Parabilis Medicines (PBLS) has a profit margin of -115483.11%, below the Healthcare sector average of 13.89%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
The latest profit margin for PBLS is -115483.11% as of June 2026. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Parabilis Medicines's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, PBLS currently prints -115483.11% for profit margin, while the sector average sits near 13.89%. That is roughly 831327.8% below the sector mean. Large gaps often invite a closer look at Parabilis Medicines's growth, margins, and balance sheet.
Profit Margin shows how effectively Parabilis Medicines converts resources into returns. At -115483.11%, PBLS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting PBLS's profit margin (-115483.11%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Parabilis Medicines's profit margin against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.